Research Analysts Issue Forecasts for ZNTL Q1 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($0.68) per share for the quarter. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.42) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36.

A number of other equities analysts also recently issued reports on the company. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Guggenheim cut their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, HC Wainwright lowered their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Trading Up 0.9 %

Shares of ZNTL stock opened at $2.16 on Friday. The business’s 50 day moving average is $2.81 and its two-hundred day moving average is $3.21. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $18.07.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka bought 60,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the purchase, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Erste Asset Management GmbH acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Aigen Investment Management LP purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $41,000. Ieq Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, Capstone Investment Advisors LLC acquired a new position in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $48,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.